Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HXP-GPOVac 10 mcg booster in volunteers from GPO NDV-HXP-S 202
TCTR20230213001Phase 2Unknown
- Sponsor
- Government Pharmaceutical Organization
- Start
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant NDV vectored vaccine for SARS-CoV-2 in coronavirus disease 2019 (COVID-19), sponsored by Government Pharmaceutical Organization. Status: unknown.
02
Drugs
recombinant NDV vectored vaccine for SARS-CoV-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20230213001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230213001.